Janssen Pharmaceuticals, Inc. (JPI) has completed the divestiture of its US license rights to Nucynta (tapentadol), Nucynta ER (tapentadol) extended-release tablets and Nucynta (tapentadol) oral solution to Depomed for $1.05 billion.
JPI's licensed US commercialization rights to Nucynta (tapentadol), Nucynta ER (tapentadol) extended-release tablets and Nucynta (tapentadol) oral solution from Grunenthal GmbH were assigned to Depomed. JPI will retain license rights to Nucynta (tapentadol), Nucynta ER (tapentadol) extended-release tablets and Nucynta (tapentadol) oral solution in Canada, Japan, and a number of other countries outside the United States.
Nucynta (tapentadol) and Nucynta ER (tapentadol) extended-release tablets are opioid-based medicines used for treatment of pain. Nucynta (tapentadol) is indicated for the management of moderate-to-severe acute pain in adults. Nucynta ER (tapentadol) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Full product labeling including Boxed Warnings for Nucynta and Nucynta ER is available at www.Nucynta.com. Nucynta (tapentadol) oral solution is an approved oral form of tapentadol that has not been launched.
Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, is dedicated to addressing and resolving the major unmet medical needs of our time.